Date: 2013-03-11
Type of information: Grant
Company: Prokarium (UK) the University of Birmingham’s Institute of Microbiology and Infection (UK)
Investors: Technology Strategy Board (UK) Biotechnology and Biological Sciences Research Council (BBSRC) (UK)
Amount: £0.4m
Funding type: grant
Planned used: The grant will allow Prokarium to complete preclinical work on its first pipeline product Typhetec®, a dual oral vaccine against typhoid and ETEC (enterotoxigenic E. coli), a major cause of diarrhoea. In addition, this grant will enable R&D to commence on a novel vaccine against Clostridium difficile, a major cause of colitis in the elderly. With this funding from the TSB and BBSRC, Prokarium and the University of Birmingham will be able to test candidates that have the potential to be developed into oral vaccines for both the developed and emerging markets.
Others: * On March 11, 2013, the consortium comprising vaccine developer Prokarium Ltd and the University of Birmingham’s Institute of Microbiology and Infection has received an award for ‘advancing the industrial application of synthetic biology’. The £0.4m grant from the Technology Strategy Board (TSB), the UK’s innovation agency, and the Biotechnology and Biological Sciences Research Council (BBSRC) has been earmarked to help fund the development of Prokarium’s Vaxonella® oral vaccine delivery platform as well as two specific vaccine candidates.
Therapeutic area: Infectious diseases
